Mlkl Knockout H9c2(2-1) Cell Line

The Mlkl Knockout H9c2(2-1) Cell Line is a CRISPR/Cas9-mediated knockout cell line generated from the H9c2(2-1) rat cardiomyoblast line. This engineered model disrupts the Mlkl gene, abolishing expression of the MLKL pseudokinase, which functions as the terminal executor of the necroptosis pathway. The cell line provides a genetically defined platform for investigating MLKL-dependent necroptotic signaling in a cardiac muscle background. By eliminating MLKL-mediated plasma membrane permeabilization, this model allows researchers to dissect necroptosis from apoptosis and other cell death modalities, facilitating precise mechanistic studies and therapeutic target validation.

The parental H9c2(2-1) cell line is a subclone of the H9c2 line originally derived from embryonic rat ventricular heart tissue. As a cardiomyoblast line, H9c2(2-1) retains the capacity for cardiac muscle cell differentiation and serves as an established in vitro model for studying cardiac muscle cell function, metabolism, and stress responses. These cells exhibit characteristic features of cardiac cells, including expression of cardiac-specific transcription factors and ion channels, making them a widely used system for research on cardiac hypertrophy, ischemia-reperfusion injury, and drug-induced cardiotoxicity. The genetic background of Rattus norvegicus provides a relevant context for translating findings to rodent models of cardiovascular disease.

MLKL is a pseudokinase that acts as the key executioner of necroptosis, a programmed necrosis initiated by RIPK1 and RIPK3 activation. Upon phosphorylation by RIPK3, MLKL oligomerizes and translocates to the plasma membrane, binding phosphatidylinositol phosphates to disrupt membrane integrity, causing cell lysis and DAMP release. This signaling is triggered by TNF-??, LPS, and interferons, and is regulated by complexes containing RIPK1, RIPK3, caspase-8, and FADD. MLKL thus mediates necrotic and inflammatory cell death in conditions such as ischemic injury and cancer.

In the H9c2(2-1) cardiomyoblast model, MLKL-mediated necroptosis has been implicated in cardiac cell death during ischemia-reperfusion injury, contributing to myocardial damage and adverse remodeling. Disruption of Mlkl in these cells abrogates the necroptotic response to pathophysiological stimuli, enabling researchers to dissect the contribution of MLKL-dependent pathways to cardiac muscle cell loss. This cell line is particularly valuable for studying the interplay between necroptosis, apoptosis, and inflammation in cardiac disease contexts, for example, by comparing responses to hypoxia/reoxygenation or chemotherapeutic agents. The Mlkl Knockout H9c2(2-1) line thus provides a powerful tool to delineate MLKL-specific effects in cardiomyocyte biology.

Typical research applications involve delineating necroptotic signaling in cardiac cells, screening for inhibitors of RIPK3/MLKL-mediated necrosis, and examining MLKL functional complexes. Experimentally, the knockout line is validated for western blotting to detect phosphorylated MLKL, RT-qPCR for Mlkl transcript quantification, MTT and LDH release assays for viability and cytotoxicity, flow cytometry with propidium iodide for membrane permeability, co-immunoprecipitation with RIPK3, and immunofluorescence to monitor MLKL translocation. For technical inquiries or additional information, please contact Ascent Research.